Crinetics Announces December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces December 2022 inducement grants: the stock options were granted as inducements material to 12 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Provides Update on CRN04777 Program


Crinetics provided an update on development of CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference


Crinetics management will participate in a fireside chat on November 30, 2022 at the 5th Annual Evercore ISI HealthCONx Conference

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update


Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2022 clinical progress including an expectation of topline data from PATHFNDR-1 in 2023

Crinetics Announces November 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces November 2022 inducement grants: the stock options were granted as inducements material to four employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).